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Syncope is a transient symptom characterized by a sudden
loss of consciousness (including by definition concomitant
loss of postural tone), with subsequent spontaneous and
relatively prompt recovery. Premonitory symptoms may or
may not warn of the event. In some cases there are no
warning symptoms, or they are lost to recall afterward.
Syncope must be differentiated from other conditions in
which loss of consciousness may be real or seem to be real,
and which thereby mimic “true” syncope. Examples of such
conditions include certain types of seizures, sleep distur-
bances, accidents, and some psychiatric conditions.
See page 787
Establishing the basis for syncope (i.e., determining the
“diagnosis”) is a prerequisite to advising patients with regard
to prognosis, and to developing an effective treatment
strategy. However, arriving at the diagnosis can be difficult,
and is often marked by the undertaking of costly and often
fruitless diagnostic procedures. In this regard, the develop-
ment and evaluation of thoughtful, evidence-based (when
possible) diagnostic guidelines/pathways for the evaluation
of patients with syncope is highly desirable (1–3). However,
because syncope is a temporary state and not a disease,
establishing the true value of such pathways is challenging
and will likely require careful assessment of outcomes in
individual patients. Only then can the diagnosis be validated
and the utility of the guideline established. This latter step
will remain a hurdle for many years to come.
In this issue of the Journal, Garcia-Civera et al. (4)
present diagnostic outcomes of an evaluation strategy for
patients with syncope. The patients were selected on the
basis of the principal criterion that the etiology of the
symptoms remained unknown despite an initial evaluation
encompassing a medical history and physical examination,
12-lead electrocardiogram (ECG), carotid sinus massage,
and 24-h ambulatory ECG monitoring, among other things.
Thereafter, the strategy reasonably relied upon certain histor-
ical and/or basic testing features in order to determine the
subsequent testing direction, an approach similar to that
advocated by the European Society of Cardiology Task Force
on Syncope (2) and others (5,6) (Table 1).
Among the 184 patients in the report by Garcia-Civera et
al. (4), patients with certain findings on initial evaluation,
such as structural heart disease, an abnormal ECG, signif-
icant arrhythmias on ambulatory monitoring, or palpitations
before syncope, underwent clinical electrophysiologic test-
ing as the next step in their assessment. The authors report
a 44% diagnostic yield in this group of 72 individuals (i.e.,
paroxysmal atrioventricular [AV] block in 14, ventricular
tachycardia in 9, supraventricular tachycardia in 5, sinus
node dysfunction in 3, and carotid sinus syndrome in 1).
Further, among 40 patients in whom electrophysiology testing
had been nondiagnostic, tilt tests were considered to provide a
diagnosis in 23 cases. Finally, of the 17 remaining undiagnosed
patients, 15 underwent implantation of an implantable loop
recorder (ILR). Two others refused. The ILR provided a
positive outcome in 8 of these 15 individuals (i.e., paroxysmal
AV block in 3, sinus arrest in 2, polymorphous ventricular
tachycardia in 2, and sinus rhythm in 1). Among patients
without the above noted initial evaluation features, tilt-table
testing was employed as the next step. This test was reported to
be diagnostic in 71% of those tested. Overall, among all
patients, the investigators report a diagnostic yield of 78%.
POSITIVE TESTS OR APPARENT DIAGNOSTIC
OBSERVATIONS: WHAT IS A DIAGNOSIS?
The diagnostic strategy employed by Garcia-Civera et al.
(4) is commendable for its organized approach, and is
generally consistent with current concepts and published
recommendations (1–3). Further, it presents a practicable
approach to the “real world” of the syncope evaluation. On
the other hand, although integration of a selective ILR
strategy with conventional diagnostic procedures such as
tilt-table testing and invasive electrophysiologic testing
seems defensible, some would argue that a more aggressive
ILR implantation strategy is already warranted on the basis
of published evidence (2,7).
Perhaps the most important observation presented by
Garcia-Civera et al. (4) is that a relatively high diagnostic
yield—within the range claimed by other investigators
(2,3)—is achievable with a few selected tests. If reproduc-
ible, these findings map the way toward minimizing waste-
ful diagnostic procedures. On the other hand, selection bias
could have played a role in the apparent outcome. For example,
if the study patients are derived from a referred population,
they may have already undergone an element of prestudy
screening evaluation by others. If such an evaluation had taken
place, and included tests other than simply the basic history,
physical examination, and 12-lead ECG, then the total num-
ber of procedures needed to make a diagnosis would be
underestimated. Future reports should provide a screening log
and a detailed description of tests performed. Furthermore,
despite the apparent care with which the investigators devel-
oped and carried out their evaluation strategy, the validity of
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the reported diagnostic yield must be considered suspect.
There are several reasons for this skepticism.
First, as noted earlier, syncope is not a “disease,” the
diagnosis of which can be readily confirmed by other tests.
In essence, the positive predictive accuracy of a diagnostic
test or set of tests cannot be readily assessed in patients with
syncope. Because syncope is an episodic symptom, the
diagnostic standard remains documentation of an abnor-
mality observed during a spontaneous event. Unfortunately,
this is only rarely possible. Consequently, absent concor-
dance of diagnostic laboratory findings and spontaneous
documented events (i.e., the gold standard) any abnormality
observed during testing must be viewed with suspicion (even
if practical necessity demands that it be acted upon). The
classic experience of Fujimura et al. (8), and the more recent
revelations by Moya et al. (7) in the ISSUE trial and others
(9,10) speak to this concern. The former demonstrated the
high frequency with which abnormal electrophysiologic
laboratory findings are misleading. In essence, Fujimura et
al. (8) summarized outcomes of electrophysiologic testing in
patients with syncope in whom bradyarrhythmias were
known to be the cause of syncope. Among 21 syncopal
patients with known symptomatic AV block or sinus pauses,
electrophysiologic testing correctly identified only 3 of 8
patients with documented sinus pauses (sensitivity 37.5%)
and 2 of 13 patients with documented AV block (sensitivity
15.4%). The ISSUE trial results, on the other hand, amply
illustrated the fact that even when pretest conditions
pointed in one direction (especially toward a tachyarrhyth-
mia origin), ILRs often revealed something different (usu-
ally a bradycardia). In this view, an early ILR strategy was
suggested to be safer and more effective than a conventional
strategy including electrophysiologic study (11).
Second, apart from the concerns regarding correlation of
electrophysiologic findings with real events, the criteria
employed by Garcia-Civera et al. (4) for establishing the
basis of syncope in the electrophysiology laboratory are at
best uncertain. For example, clinical cardiac electrophysi-
ologists are well aware of the historical debate that focused
on the clinical relevance of even seemingly straightforward
measurements such as the HV interval. In this regard, the
authors do not clearly state their diagnostic touchstones, but
they do refer to the communication of the European Society
of Cardiology Task Force on Syncope Evaluation (1). In
their so doing, however, it is crucial for the reader to
understand what the task force really said. Careful reading
of that cautiously phrased document reveals that the task
force members were not totally convinced that indisputable
diagnostic criteria had been established. For instance, in
regard to sinus node function studies they stated that the
CSNRT had to be “very prolonged.” Based on examination
of the text, it appears that at the very least this implies a
duration800 ms based on the work of Menozzi et al. (12).
However, as also clearly stated in the text, such a finding
corresponds only to an eightfold increment of syncope risk,
and is not an absolute marker of syncope origin. Similar
differences of interpretation are clear for other criteria used by
the authors, including, for example, the questionable diagnostic
importance of an HV interval 70 ms, or an otherwise
asymptomatic pause 3,000 ms during carotid sinus massage.
Third, given the limitations of diagnostic testing in the
absence of a gold standard, one might argue that in most
cases the reliability of a purported diagnosis can only be
estimated if, during the course of randomized controlled
trials, an apparently diagnosis-appropriate treatment results
in fewer syncope recurrences. In several important clinical
scenarios, such as acquired complete heart block and syn-
cope associated with life-threatening ventricular tachyar-
rhythmias, evidence of treatment efficacy (i.e., prevention of
syncope recurrences) appears to be adequately substantiated
despite absence of randomized controlled trials. On the
other hand, in conditions such as neurally mediated vaso-
vagal syncope, the efficacy of current pharmacologic treat-
ments is less certain, and multicenter randomized studies are
essential. Further, these multicenter studies must take into
account the likelihood (or lack thereof) of a spontaneous
untreated recurrence developing during the planned follow-
up. Thus, as suggested by Sheldon et al. (13), studies should
incorporate individuals with an established history of mul-
tiple faints. In many studies, including that of Garcia-
Cervia et al. (4), patients qualified for inclusion despite
having had relatively few preceding syncope events. In such
circumstances, absent extremely long follow-up, the effect of
treatment cannot be readily used to verify the diagnosis. To
date, with the exception of three recently completed pacing
trials in patients with recurrent vasovagal faints (14–16), the
evaluation and treatment of syncope has not been the
subject of large-scale clinical study using “high recurrence
risk” populations. Indeed, the literature on syncope diag-
nostic testing and treatment is largely composed of case
Table 1. Factors Determining Syncope Diagnostic
Evaluation Strategy*
Diagnostic goals
Establish a correlation between symptoms and detected abnormalities
Assess prognosis
Initiate appropriate treatment plan.
Key steps
Obtain detailed medical history (including bystanders/relatives)
Identify status of underlying structural heart disease (physical exam,
echo)
Factors determining need for further tests
Evidence for structural disease
Certainty of the initial clinical impression
Number and frequency of syncopal events
Family history of syncope or sudden death
Occurence of injury or accident
Patient’s occupation, avocation (possible high risk of injury to patient/
public)
Ultimate gold standard
Diagnosis-appropriate treatment prevents syncope recurrence during
long-term follow-up
*Modified from Benditt DG, Ermis C, Lurie KG, Sakaguchi S. Syncope. In: Yusuf
S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, editors. Evidence Based Cardiology.
2nd edition. London: BMJ Books, 2003:619–33.
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series, cohort studies, or retrospective analyses of already
existing data. For the most part, the impact of testing on
guiding therapy and reducing syncope recurrences cannot be
discerned from these methods of research. Until randomized
controlled studies are undertaken, the true “diagnostic yield”
associated with any diagnostic strategy must remain suspect. In
other words, a positive test does not a diagnosis make.
Fourth, even the recording of an arrhythmia in conjunc-
tion with a spontaneous event may not provide a definitive
diagnosis. For instance, asystole of sufficient duration to
cause syncope may occur as a result of sinus node dysfunc-
tion, or carotid sinus syndrome, or vasovagal syncope,
among other things. Establishing the true diagnosis, a
necessity in order to discuss prognosis and choose the most
appropriate therapy, depends on examining additional layers
of what can be a very tough onion.
Finally, the genesis of syncope is often multifactorial, and
more than one pathophysiologic factor may contribute to
the symptoms. For instance, in the setting of valvular aortic
stenosis or left ventricular outflow tract obstruction, syncope
is not solely the result of restricted cardiac output, but may
be in part due to inappropriate neurally mediated reflex
vasodilation and/or primary cardiac arrhythmias (17). Sim-
ilarly, a neural reflex component (preventing or delaying
vasoconstrictor compensation) appears to play an important
role when syncope occurs in association with certain brady-
and tachyarrhythmias (18–20). Thus, multiple mechanisms
should be investigated even when an apparent cause is
already detected. This is particularly important for the
choice of the most efficacious treatment.
LIMITATIONS OF DIAGNOSTIC TECHNOLOGY
As alluded to earlier, syncope is a transient symptom.
Typically patients are most often asymptomatic at the time
of evaluation. “Capturing” a spontaneous event during
diagnostic testing is uncommon, apart from the case of
prolonged ILR monitoring. However, even when it does
happen, current technology limits our learning all that we
would like to know. Thus, using available ILRs we can
obtain ECG recordings during episodic symptom events for
considerable periods of time. Nevertheless, even in the case
of ILR-documented syncope, we cannot evaluate blood
pressure simultaneously, and we cannot obtain a reliable
marker of a patient’s exertional status at the time of recorded
events. Alternatively, we can record blood pressure more or
less noninvasively, but we cannot obtain an adequate-quality
simultaneous ECG or electroencephalogram. Implantable
blood pressure/ECG devices are in development but remain
a long way from clinical application. As a result, despite
substantial sophisticated technology on our side, the diag-
nostic evaluation largely remains indirect, and limited to
discerning susceptibility to physiologic states that could cause
loss of consciousness. In essence, the potential causal rela-
tionship between a diagnostic abnormality and syncope in a
given patient is presumptive most of the time. Of necessity,
then, there must remain considerable uncertainty regarding
the confidence with which “diagnostic” testing results in
establishing the most probable cause of symptoms.
A PRACTICABLE “DIAGNOSTIC” STRATEGY
In the evaluation of patients with syncope, the critical first
step is the obtaining of a detailed medical history of
symptomatic events by an experienced interviewer, includ-
ing the interviewing of knowledgeable bystanders. The
components of the history taking require considerable
thought and thoroughness in their own right (2). Next, a
physical examination along with certain basic tests (ECG
and echocardiogram) should be undertaken to ascertain
whether there is evidence of apparently clinically important
underlying structural heart disease. In this regard, echocar-
diography rarely provides a definitive basis for syncope.
Nonetheless, the echocardiogram is invaluable given the
importance of identifying underlying structural heart dis-
ease. Further, in some cases the echocardiogram may
provide indirect clues to the cause of syncope if, for example,
hypertrophic obstructive cardiomyopathy, severe valvular
aortic stenosis, intracardiac tumor (e.g., myxoma), or anom-
alous origin of one or more coronary arteries is detected.
Exercise testing is not often useful, but may be included if
syncope occurred with exertion or if ischemic heart disease
is suspected. Thereafter, the need for further specialized
diagnostic testing will vary depending on various factors,
including the certainty of the initial clinical impression,
findings during physical examination, the number and
frequency of syncopal events reported, the occurrence of
injury or accident, and the presence of a family history of
syncope or sudden death. Additionally it is important to
consider the potential risks associated with the individual’s
occupation (for example, commercial vehicle driver, ma-
chine operator, professional athlete, sign painter, surgeon)
or avocation (for example, skier, swimmer) that might be
encountered if syncope recurred.
A key point at this phase of the evaluation is the question
whether structural heart disease is present or absent. Ignor-
ing the fact that “structural heart disease” is not a term that
is readily defined, its absence is widely accepted to exclude
for the most part a cardiac cause of syncope. In a recent
study (21), heart disease was an independent predictor of
cardiac cause of syncope, with a sensitivity of 95% and a
specificity of 45%; by contrast, the absence of heart disease
allowed exclusion of a cardiac cause of syncope in 97% of the
patients. As a rule, if structural heart disease is deemed to be
absent, then tilt-table testing and related assessment of
autonomic nervous system function are the most useful
diagnostic tests to select next. Neurally mediated vasovagal
syncope and orthostatic hypotension are by far the most
frequent causes of syncope in this setting. On the other
hand, if abnormal cardiac findings are identified, their
functional significance should be characterized by hemody-
namic and/or angiographic assessment as appropriate. Fur-
thermore, because cardiac arrhythmias are a common cause
of syncope in the setting of structural cardiac disease,
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assessing the patient’s susceptibility to tachy- and brady-
arrhythmias by various ambulatory ECG recording tech-
niques (especially wearable or implantable loop recorders)
may be warranted. The risk of injury during a spontaneous,
albeit recorded, syncope recurrence is a real concern. Ulti-
mately, electrophysiologic testing may be needed, but inter-
pretation of findings must be undertaken with caution for
reasons outlined earlier. Although there are no randomized
studies, the evidence seems sufficient to indicate that elec-
trophysiologic testing is most likely to be diagnostic in
individuals with underlying structural heart disease, and that
the induction of reentry supraventricular or monomorphic
ventricular tachycardia in a patient with syncope is likely to
be significant. These arrhythmias are rarely innocent by-
standers. Nonetheless, demonstration of their hemody-
namic significance in an individual patient may necessitate
their induction with the patient in an appropriately secured
upright tilt position. Tilt-table testing would follow if the
diagnosis remains in doubt (2). Strong evidence supports
the view that specialized neurologic studies are only rarely
useful as part of the syncope evaluation (2).
SUMMARY
The ultimate goal of diagnostic testing is to establish a
sufficiently strong correlation between syncope and detected
abnormalities to permit both an assessment of prognosis and
initiation of an appropriate treatment plan. Randomized con-
trolled trials demonstrating that presumptive diagnostic out-
comes lead to effective therapy are needed in order to confirm
that the detected “cause(s)” of syncope are indeed real.
When it comes to the assessment of syncope, unnecessary
and cost-ineffective testing remains an unfortunate feature
of current clinical diagnostic practice. Pathways and guide-
lines offer the potential of helping physicians achieve diag-
nostic goals in a more expeditious and efficient manner, and
studies such as that provided by Garcia-Cervia et al. (4) in
this issue of the Journal are important in validating their use.
However, even in the setting of well-established guidelines,
physician expertise in the taking of the medical history and
evaluating the pertinent physical findings, and thereby being
in a position to select appropriate subsequent testing and
interpret test outcomes, varies widely. Ongoing education is
needed. An interdisciplinary educational effort incorporating
emergency room physicians, general practitioners, internists,
pediatricians, neurologists, and cardiologists is essential to
bridge this gap. The European Society of Cardiology, through
the multinational educational efforts of its Task Force on
Syncope, has taken an important step in this direction.
Acknowledgments
The authors would like to thank the members of the
European Society of Cardiology Task Force on the Syncope
Evaluation for the many discussions and debates that have
undoubtedly lead to concepts outlined above, and Wendy
Markuson for assistance in preparation of the manuscript.
Reprint requests and correspondence: Dr. David G. Benditt,
Cardiac Arrhythmia Center, University of Minnesota Medical
School, MMC 508, 420 Delaware Street SE, Minneapolis, Min-
nesota 55455. E-mail: bendi001@maroon.tc.umn.edu.
REFERENCES
1. Benditt DG, Ferguson DW, Grubb BP, et al. Tilt-table testing for
assessing syncope. An American College of Cardiology expert consen-
sus document. J Am Coll Cardiol 1996;28:263–75.
2. Brignole M, Alboni P, Benditt D, et al. Guidelines on management
(diagnosis and treatment) of syncope. Eur Heart J 2001;22:1256–306.
3. Linzer M, Yang E, Estes M III, et al. Diagnosing syncope. Part I:
value of history, physical examination, and electrocardiography. Ann
Intern Med 1997;126:989–96.
4. Garcia-Civera R, Ruiz-Granell R, Morell-Cabedo S, et al. Selective
use of diagnostic tests in patients with syncope of unknown cause.
J Am Coll Cardiol 2003;41:787–90.
5. Olshansky B. Syncope: overview and approach to management. In:
Syncope: Mechanisms and Management. Grubb BP, Olshansky B,
editors. Armonk, NY: Futura Publishing Co., 1998:15–71.
6. Benditt DG, Ermis C, Lurie KG, Sakaguchi S. Syncope. In: Yusuf S,
Cairns JA, Camm AJ, Fallen EL, Gersh BJ, editors. Evidence Based
Cardiology. 2nd edition. London: BMJ Books, 2003:619–33.
7. Moya A, Brignole M, Menozzi C, et al., and ISSUE Investigators.
Mechanism of syncope in patients with isolated syncope and in
patients with tilt-positive syncope. Circulation 2001;104:1261–7.
8. Fujimura O, Yee R, Klein G, Sharma A, Boahene A. The diagnostic
sensitivity of electrophysiologic testing in patients with syncope caused
by transient bradycardia. N Engl J Med 1989;321:1703–7.
9. Brignole M, Menozzi C, Moya A, et al. The mechanism of syncope in
patients with bundle branch block and negative electrophysiologic test.
Circulation 2001;104:2045–50.
10. Menozzi C, Brignole M, Garcia-Civera R, et al. Mechanism of
syncope in patients with heart disease and negative electrophysiologic
test. Circulation 2002;105:2741–5.
11. Menozzi C, Brignole M, Alboni P, et al. The natural course of
untreated sick sinus syndrome and identification of the variables
predictive of unfavourable outcome. Am J Cardiol 1998;82:1205–9.
12. Krahn A, Klein GJ, Yee R, Skanes AC. Randomized assessment of
syncope trial. Conventional diagnostic testing versus a prolonged
monitoring strategy. Circulation 2001;104:46–51.
13. Sheldon R, Rose S, Flanagan P, Koshman ML, Killam S. Risk factors
for syncope recurrence after a positive tilt-table test in patients with
syncope. Circulation 1996;93:973–81.
14. Connolly SJ, Sheldon R, Roberts RS, Gent M, and the Vasovagal
Pacemaker Study Investigators. The North American vasovagal pace-
maker study (VPS): a randomized trial of permanent cardiac pacing for
the prevention of vasovagal syncope. J Am Coll Cardiol 1999;33:16–20.
15. Sutton R, Brignole M, Menozzi C, et al., for the VASIS Investigators.
Dual-chamber pacing is efficacious in treatment of neurally-mediated
tilt-positive cardioinhibitory syncope. Pacemaker versus no therapy: a
multicentre randomized study. Circulation 2000;102:294–9.
16. Ammirati F, Colivicchi F, Santini M, et al. Permanent cardiac pacing
versus medical treatment for the prevention of recurrent vasovagal
syncope. A multicenter, randomized, controlled trial. Circulation
2001;104:52–6.
17. Johnson AM. Aortic stenosis, sudden death, and the left ventricular
baroreceptors. Br Heart J 1971;33:1–5.
18. Leitch JW, Klein GJ, Yee R, et al. Syncope associated with supraven-
tricular tachycardia: an expression of tachycardia or vasomotor re-
sponse. Circulation 1992;85:1064–71.
19. Brignole M, Gianfranchi L, Menozzi C, et al. Role of autonomic
reflexes in syncope associated with paroxysmal atrial fibrillation. J Am
Coll Cardiol 1993;22:1123–9.
20. Alboni P, Menozzi C, Brignole M, et al. An abnormal neural reflex
plays a role in causing syncope in sinus bradycardia. J Am Coll Cardiol
1993;22:1130–4.
21. Alboni P, Brignole M, Menozzi C, et al. The diagnostic value of
history in patients with syncope with or without heart disease. J Am
Coll Cardiol 2001;37:1921–8.
794 Benditt and Brignole JACC Vol. 41, No. 5, 2003
Editorial Comment March 5, 2003:791–4
